GABBR1

Gamma-aminobutyric acid type B receptor subunit 1 · Q9UBS5 · GABBR1 on Sugi Atlas →

19,138 patent compounds predicted against GABBR1, 10,018 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Baclofen (SCHEMBL19333)	1.00	8/20
Baclofen (SCHEMBL19334)	1.00	8/20
Arbaclofen (SCHEMBL351220)	1.00	8/20
SCHEMBL349306	0.56	8/20
Phaclofen (SCHEMBL339995)	0.57	7/20
SCHEMBL351660	0.57	7/20
SCHEMBL339757	1.00	6/20
SCHEMBL339758	1.00	6/20
Phenibut (SCHEMBL340838)	1.00	6/20
SCHEMBL342399	1.00	6/20
Phenibut (SCHEMBL351501)	1.00	6/20
SCHEMBL351502	0.70	6/20
SCHEMBL351702	0.70	6/20
SCHEMBL523877	0.59	6/20
Hydrochloric Acid (SCHEMBL191270)	0.56	6/20
Hydrochloric Acid (SCHEMBL191271)	0.56	6/20
SCHEMBL342850	0.56	6/20
SCHEMBL341755	0.56	6/20
SCHEMBL296405	0.53	6/20
Hydrochloric Acid (SCHEMBL560383)	0.50	6/20

Clinical trials — most relevant to GABBR1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Computational Assessment of GABA Receptor Modulation in PTSD	PHASE4	RECRUITING
The Effect of Oral Baclofen and Botulinum Toxin Treatments in Hemiplegic Spasticity on the Nociceptive Flexor Reflex	PHASE4	COMPLETED
Safety of Ramelteon in Elderly Subjects	PHASE4	COMPLETED
Evaluating the Safety of Acute Baclofen in Methadone-maintained Individuals With Opiate Dependence.	PHASE4	COMPLETED
Clonazepam Effects on Brain Oscillations and Cognition in Schizophrenia	PHASE4	WITHDRAWN
Safety and Efficacy Study of Ramelteon in Subjects With Chronic Insomnia	PHASE3	COMPLETED
Efficacy and Safety of Ramelteon Combined With Gabapentin in Treating Patients With Insomnia	PHASE2	COMPLETED
Safety and Efficacy of Ramelteon and Doxepin in Subjects With Chronic Insomnia	PHASE2	COMPLETED
Diazepam Trial in GAD65 Associated Epilepsy	PHASE1/PHASE2	WITHDRAWN
Effects of Baclofen on Presynaptic Inhibition in Humans	PHASE2	WITHDRAWN
PET Whole Body Imaging Using a Peripheral Benzodiazepine Receptor Ligand [C-11]PBR28	PHASE1	COMPLETED
PET Imaging of Brain Peripheral Benzodiazepine Receptors	PHASE1	COMPLETED
The Use of Glutamic Acid Decarboxylase (GAD) and Gamma-Amino Butyric Acid (GABA) in the Treatment of Type I Diabetes	PHASE1	COMPLETED
MEG Study of Acute STX209 Effects in ASD	EARLY_PHASE1	COMPLETED
Synaptic Mechanisms of Continuous Theta Burst Stimulation in Depression	EARLY_PHASE1	RECRUITING
Imaging the Effects of Zolpidem and Alprazolam in Healthy Volunteers at 3T	EARLY_PHASE1	UNKNOWN
Brain Changes in Patients With Focal Hand Dystonia	nan	COMPLETED
GABA Biomarkers in Dravet Syndrome	nan	RECRUITING
Investigating the Role of Diazepam on Brain Function and Chemistry in Psychosis Risk	nan	COMPLETED
Association of Brain Derived Neurotrophic Factor (BDNF) rs6265 Gene Polymorphism With Susceptibility to Epilepsy	nan	UNKNOWN
Cenobamate Efficacy in Individuals With Autoimmune Epilepsy	nan	ENROLLING_BY_INVITATION
Effect of Gabapentin on GABA Concentration and Emotional Processing	nan	COMPLETED
Study of GABA-A Receptors in the Generation of Tics in Patients With Tourette's Syndrome	nan	COMPLETED
Protocol Assessment of Motor Cortex rTMS for Treating Neuropathic Pain	nan	RECRUITING
The Effect of Repetitive Transcranial Magnetic Stimulation (rTMS) on Working Memory	nan	COMPLETED
Effects of Flumazenil on Brain Excitability	nan	COMPLETED
Pilot Study Evaluating Neuro-Imaging Correlates of Epigenetic Finding in Prediction of Chronic Postsurgical Pain	nan	UNKNOWN
Butyrate Supplementation in Children With Autism Spectrum Disorder (ASD) and Functional Gastrointestinal Disorders	nan	RECRUITING
Effects of Gene Polymorphism After Transcranial Cranial Direct Current Stimulation on the Corticobulbar Excitability	nan	COMPLETED
Clinical-Genetic Variation in GABA/Alcohol Sensitivity	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a GABBR1 binder may also engage these)

Protein	Name	Similarity
Q9Z0U4	—	0.996	Q9Z0U4 →
Q9WV18	—	0.996	Q9WV18 →
P35439	—	0.963	P35439 →
P35438	—	0.963	P35438 →
GRIN1	Glutamate receptor ionotropic, NMDA 1	0.961	landscape →
Q5R1P0	—	0.955	Q5R1P0 →
A0A1L8F5J9	—	0.952	A0A1L8F5J9 →
Q9Y2E8	—	0.948	Q9Y2E8 →
Q8R4D1	—	0.941	Q8R4D1 →
Q4L208	—	0.941	Q4L208 →
Q5ZJ75	—	0.938	Q5ZJ75 →
Q13888	—	0.934	Q13888 →
MTAP	S-methyl-5'-thioadenosine phosphorylase	0.934	landscape →
Q91ZH7	—	0.932	Q91ZH7 →
Q90812	—	0.932	Q90812 →
Q5SP67	—	0.932	Q5SP67 →
F6RQL9	—	0.932	F6RQL9 →
F1LTR1	—	0.931	F1LTR1 →
Q5ZJQ7	—	0.930	Q5ZJQ7 →
Q6P1K8	—	0.930	Q6P1K8 →
Q0VC00	—	0.929	Q0VC00 →
P35347	—	0.928	P35347 →
SSU72	RNA polymerase II subunit A C-terminal domain phosphatase SSU72	0.928	landscape →
O62772	—	0.927	O62772 →
P35353	—	0.927	P35353 →
Q4KLK9	—	0.926	Q4KLK9 →
Q17QI2	—	0.926	Q17QI2 →
Q76LL8	—	0.926	Q76LL8 →
CRHR1	Corticotropin-releasing factor receptor 1	0.926	landscape →
GABRG3	Gamma-aminobutyric acid receptor subunit gamm	0.924	landscape →